Evidence map›Paper›PMID 25311260›Full record

ArticleInternational journal of radiation oncology, biology, physics2014

Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system.

Susan L McGovern, M Fatih Okcu, Mark F Munsell, Nancy Kumbalasseriyil, David R Grosshans, Mary F McAleer, Murali Chintagumpala, Soumen Khatua, Anita Mahajan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Susan L McGovernDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: slmcgove@mdanderson.org.
M Fatih OkcuTexas Children's Hematology and Oncology Centers, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Mark F MunsellDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Nancy KumbalasseriyilDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
David R GrosshansDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Mary F McAleerDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Murali ChintagumpalaTexas Children's Hematology and Oncology Centers, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Soumen KhatuaDepartment of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Anita MahajanDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

purposeAtypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system is a rare cancer primarily affecting children younger than 5 years old. Because patients are young and receive intensive chemotherapy, there is concern regarding late radiation toxicity, particularly as survival rates improve. Therefore, there is interest in using proton therapy to treat these tumors. This study was undertaken to investigate outcomes and acute toxicities associated with proton therapy for AT/RT. METHODS AND MATERIALS: The records of 31 patients with AT/RT treated with proton radiation from October 2008 to August 2013 were reviewed. Demographics, treatment characteristics, and outcomes were recorded and analyzed.

resultsMedian age at diagnosis was 19 months (range, 4-55 months), with a median age at radiation start of 24 months (range, 6-62 months). Seventeen patients received local radiation with a median dose of 50.4 GyRBE (range, 9-54 GyRBE). Fourteen patients received craniospinal radiation; half received 24 GyRBE or less, and half received 30.6 GyRBE or more. For patients receiving craniospinal radiation, the median tumor dose was 54 GyRBE (range, 43.2-55.8 GyRBE). Twenty-seven patients (87%) completed the planned radiation. With median follow-up of 24 months for all patients (range, 3-53 months), median progression-free survival was 20.8 months and median overall survival was 34.3 months. Five patients (16%) developed clinical findings and imaging changes in the brainstem 1 to 4 months after radiation, consistent with radiation reaction; all cases resolved with steroids or bevacizumab.

conclusionsThis is the largest report of children with AT/RT treated with proton therapy. Preliminary survival outcomes in this young pediatric population are encouraging compared to historic results, but further study is warranted.

Indexed as

Angiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabBrain NeoplasmsBrain StemCentral Nervous System NeoplasmsChild, PreschoolCraniospinal IrradiationDisease-Free SurvivalDisease ProgressionFemaleHumansInfantMaleProton TherapyRadiation InjuriesAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumab

Identifiers

PMID25311260
PMCPMC4327980
OpenAlexW1965074458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.